BioSpace News Archive

Neurogene Inc. (NASDAQ: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that its NGN-401 gene therapy for Rett syndrome has been selected to participate in the U.S. Food and Drug Administration (FDA) Support for Clinical Trials Advancing Rare Disease Therapeutics (START) Pilot Program.

Evaxion Biotech A/S reported data from its ongoing Phase 2 study at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024.

Mineralys Therapeutics, Inc. today announced that management will be participating in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference, being held in Miami, FL on June 10-13, 2024.

Indaptus Therapeutics, Inc today announced updated data from its ongoing Phase 1 clinical trial of Decoy20 in patients with solid tumors.

Replimune Group, Inc. today presented two oral presentations highlighting promising clinical data from its RP1 and RP2 programs at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31-June 4 in Chicago.

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY) announced today that the final results of the Phase IIa ALICE study evaluating iadademstat in combination with azacitidine in unfit patients with newly diagnosed acute myeloid leukemia (AML) were published online in The Lancet Hematology.

Rhythm Pharmaceuticals, Inc. today announced that David Meeker, M.D., Chair, President and Chief Executive Officer, will participate in a fireside chat at Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10, 2024 at 9:20 a.m.

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, announced that the Company will participate in two upcoming healthcare conferences in June.

NewGenIvf Group, a comprehensive fertility services provider in Asia helping couples and individuals obtain access to fertility treatments, announced the execution of a non-binding term sheet regarding a proposed reverse merger with pharmaceutical company COVIRIX Medical Pty Ltd.

Alkermes plc announced new data from the full narcolepsy type 1 cohort of a phase 1b, proof-of-concept study evaluating ALKS 2680, the company’s novel, investigational, oral orexin 2 receptor agonist in development as a once-daily treatment for narcolepsy.